New Structure of Business Operations for a Global Pharmaceutical Company

TakedaAs part of its "Transformation into a New Takeda", Takeda Pharmaceutical Company Limited ("Takeda") has implemented several strategies to realize its corporate vision of achieving "sustainable growth" by 2015 through "innovation" and "culture". The latest development came with the recent closing of the Nycomed acquisition, whereby Takeda took another significant step towards globalization. Today, Takeda announces the establishment of the positions of Chief Medical & Scientific Officer (CMSO) and Chief Commercial Officer (CCO), to strengthen the company's governance and business operations as it moves forward to fully integrate the Nycomed organization and become a truly global pharmaceutical company.

In order to further strengthen its global research and development activities, Takeda has abolished the position of Chief Scientific Officer and established the new position of CMSO. Takeda board member Dr. Tadataka Yamada, a medical doctor and scientist with vast global experience in pharmaceutical R&D, has been appointed CMSO to boost research and development productivity by driving innovation and skillfully allocating resources.

In addition, the positions of International Operations (Americas/Europe) and International Operations (North Asia) have been abolished to be replaced by the CCO, who will preside over Takeda's global sales structure (with the exclusion of Millennium and Japanese domestic sales), including most former Nycomed countries and functions. Takeda has appointed board member Dr. Frank Morich as CCO, who has extensive experience at top management in the global pharmaceutical industry. Dr. Morich will drive sales strategies in the important US and EU markets, and also in the fast-growing emerging markets.

Takeda is continually challenging itself to create innovative medicines that transform treatment paradigms to prevent and cure disease, focusing particularly on fields with unmet medical needs, and will continue to globalize its business to deliver its products to patients and health care providers worldwide.

Takeda Pharmaceutical Company Limited
Located in Osaka, Japan, Takeda (TSE:4502) is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products.

Most Popular Now

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

Repurposed drug found to be effective against Zika…

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus - and blocked transmiss...

More stroke patients may receive crucial treatment…

More patients could be eligible for critical treatments to remove or dissolve blood clots that cause strokes, according to a new treatment guideline issued by the America...

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

Cells of 3 advanced cancers die with drug-like com…

Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggres...

Pfizer announces positive top-line results for pot…

Pfizer Inc. has announced that REFLECTIONS B3281006, a comparative safety and efficacy study of PF-05280586 versus MabThera® (rituximab-EU), met its primary endpoint. PF-...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]